Candriam S.C.A. Nuvalent, Inc. Transaction History

Candriam S.C.A.

$15.6 Billion
Q1 2025

A detailed history of Candriam S.C.A. transactions in Nuvalent, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 354,129 shares of NUVL stock, worth $27.7 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

354,129

Previous 368,095 3.79%

Holding current value

$27.7 Million

Previous $28.8 Million 12.84%

% of portfolio

0.16%

Previous 0.17%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 14, 2025	SELL	$67.38 - $88.96 $941,029 - $1.24 Million	-13,966 Reduced 3.79%	354,129 $25.1 Million
Q4 2024 Feb 06, 2025	BUY	$77.87 - $104.93 $3.87 Million - $5.22 Million	49,728 Added 15.62%	368,095 $28.8 Million
Q3 2024 Nov 13, 2024	BUY	$67.44 - $112.17 $3.8 Million - $6.32 Million	56,359 Added 21.51%	318,367 $32.6 Million
Q2 2024 Aug 05, 2024	SELL	$62.76 - $81.61 $1.38 Million - $1.8 Million	-22,001 Reduced 7.75%	262,008 $19.9 Million
Q1 2024 May 03, 2024	BUY	$72.35 - $88.99 $289,400 - $355,960	4,000 Added 1.43%	284,009 $21.3 Million
Q4 2023 Feb 14, 2024	SELL	$42.42 - $80.28 $2.97 Million - $5.62 Million	-70,008 Reduced 20.0%	280,009 $20.6 Million
Q3 2023 Nov 13, 2023	BUY	$39.12 - $49.85 $2.74 Million - $3.49 Million	70,001 Added 25.0%	350,017 $16.1 Million
Q2 2023 Aug 08, 2023	SELL	$23.58 - $44.68 $1.03 Million - $1.96 Million	-43,835 Reduced 13.54%	280,016 $11.8 Million
Q1 2023 May 12, 2023	BUY	$25.42 - $33.52 $1.66 Million - $2.19 Million	65,202 Added 25.21%	323,851 $8.45 Million
Q4 2022 Feb 13, 2023	BUY	$18.46 - $36.37 $4.77 Million - $9.41 Million	258,649 New	258,649 $7.7 Million

Others Institutions Holding NUVL

# of Institutions

216

Shares Held

60.9M

Call Options Held

319K

Put Options Held

211K

View Full List

About Nuvalent, Inc.

Ticker NUVL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,977,800
Market Cap $3.36B
Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...

More about NUVL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account